Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis

Applied Sciences

PatrickImesch¹  Julian MatthiasMetzler²  Daniel Fink³ 

[1] Department of Gynecology, University Hospital Zurich, Frauenklinikstrase 10, 8091 Zurich, Switzerland;Department of Gynecology, University Hospital Zurich, Frauenklinikstrasse 10, 8091 Zurich, Switzerland;Faculty of Medicine, University of Zurich, Pestalozzistrasse 3/5, 8091 Zurich, Switzerland;

关键词: ibrutinib;    Bruton’s tyrosine kinase;    Btk;    kinase inhibitor;    ovarian cancer;    gynecological oncology;   

DOI  :  10.3390/app11010222

来源: DOAJ

【 摘 要 】

Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase, an enzyme central in B cell development. It is indicated as a therapy for certain hematological diseases such as chronic lymphocytic leukemia (CLL), but also exerts off-target effects on several receptors and kinases. In this paper, we hypothesize that ibrutinib may suppress the tumor marker CA-125 in ovarian cancer. The hypothesis is based on an observation of CA-125 normalization in a patient with low-grade serous ovarian cancer who received ibrutinib for concurrent CLL. We propose a mechanistic model explaining this possible drug effect as a foundation for further research.

【 授权许可】

Unknown